search
GLP-1 weight loss drugs
Trends
- 1One in six children on GLP-1 drugs develop deficiencies●Study: One in six children on GLP-1 drugs developed nutritional deficiencies
A new study reports that about one in six children taking GLP-1 medications, such as Ozempic and Wegovy, developed nutritional deficiencies while on the drugs. The findings raise concerns that appetite suppression and reduced intake may leave some children short on key nutrients, prompting calls for closer monitoring of children prescribed these increasingly used weight-loss medications.
- 2Weight loss drugs may help treat reproductive health issues▼Weight loss drugs could help treat women’s reproductive health issues, experts say
Health experts say weight loss drugs such as GLP-1 medications could offer benefits beyond slimming, potentially helping treat women's reproductive health issues. The suggestion points to a possible new use for a class of medicines already in high demand, and it is drawing attention to how obesity-related treatments might intersect with conditions like polycystic ovary syndrome and fertility problems.
- 3Hims & Hers Unveils AI-Driven Weight Loss Platform▼Hims & Hers Health (HIMS) Unveils AI Native Weight Loss Care Platform
Telehealth company Hims & Hers Health has announced an AI-native weight loss care platform, building artificial intelligence into how patients receive weight loss treatment and support. The launch positions the company to compete more aggressively in the fast-growing market for weight loss care, where demand for GLP-1 drugs and digital health services has surged. Investors and industry watchers are watching how the move affects the company's growth prospects.
- 4Study links GLP-1 drugs in children to nutritional deficiencies●Interactive: Study links GLP-1 use in children to nutritional deficiencies
A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.